You’re correct that the companies have never disclosed that AAB-001 is the second antibody collaboration, but there aren’t any other ELN antibodies that fit the bill.
I assume that the AAB-001 project is still viable, but confirmation from the company would be helpful.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”